{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:49:51Z","timestamp":1787579391675,"version":"build-2736575974"},"reference-count":11,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with newly diagnosed Graves disease often elect for treatment with the drug methimazole (MMI) over alternative therapies. However, MMI can commonly result in skin allergy that in severe cases can lead to discontinuation of therapy. We present a case of Graves thyrotoxicosis with a delayed hypersensitivity reaction while on MMI. The patient was successfully treated with a novel, individualized, 27-day desensitization protocol that resulted in tolerance of MMI with subsequent improvement in thyroid indices. Previous literature has offered various rapid desensitization protocols to MMI for immediate type hypersensitivity reactions. However, in nonimmediate, delayed hypersensitivity reactions, a slower desensitization protocol can be considered. As demonstrated in this case, desensitization to MMI is a reasonable alternative in patients who wish to avoid definitive therapy who develop an initial adverse reaction to MMI, as this can occur in up to 13% of treated cases.<\/jats:p>","DOI":"10.1210\/jcemcr\/luae066","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T08:13:20Z","timestamp":1716797600000},"source":"Crossref","is-referenced-by-count":3,"title":["Methimazole Desensitization in a Patient Experiencing a Thionamide-induced Hypersensitivity Reaction"],"prefix":"10.1210","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-3572","authenticated-orcid":false,"given":"Joseph","family":"Arguinchona","sequence":"first","affiliation":[{"name":"Department of Medicine, Mayo Clinic Arizona , Scottsdale, AZ 85259 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-6787","authenticated-orcid":false,"given":"Avanika","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Mayo Clinic Arizona , Scottsdale, AZ 85259 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-6130","authenticated-orcid":false,"given":"Alexei","family":"Gonzalez-Estrada","sequence":"additional","affiliation":[{"name":"Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic Arizona , Scottsdale, AZ 85259 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-6709","authenticated-orcid":false,"given":"Eleanna","family":"De Filippis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Mayo Clinic Arizona , Scottsdale, AZ 85259 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"issue":"9","key":"2024062702115049100_luae066-B1","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2013-1954","article-title":"Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis","volume":"98","author":"Sundaresh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024062702115049100_luae066-B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.14374","article-title":"Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves\u2019 disease: a review of the literature","volume":"95","author":"El Kawkgi","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2024062702115049100_luae066-B3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/MED.0000000000000656","article-title":"Long-term antithyroid drug therapy","volume":"28","author":"Cooper","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"2024062702115049100_luae066-B4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eprac.2020.10.019","article-title":"Desensitization to methimazole","volume":"27","author":"Mazhari","year":"2021","journal-title":"Endocr Pract"},{"issue":"4","key":"2024062702115049100_luae066-B5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.aace.2021.02.002","article-title":"Methimazole desensitization in a 4-year-old with refractory Graves disease","volume":"7","author":"Schneider Aguirre","year":"2021","journal-title":"AACE Clin Case Rep"},{"issue":"4","key":"2024062702115049100_luae066-B6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024062702115049100_luae066-B7","doi-asserted-by":"crossref","first-page":"590991","DOI":"10.3389\/fphar.2020.590991","article-title":"Mechanisms of drug desensitization: not only mast cells","volume":"11","author":"Vultaggio","year":"2020","journal-title":"Front Pharmacol"},{"issue":"6","key":"2024062702115049100_luae066-B8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2024062702115049100_luae066-B9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/EJE-20-1490","article-title":"Preferences of patients and clinicians for treatment of Graves\u2019 disease: a discrete choice experiment","volume":"184","author":"van Kinschot","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2024062702115049100_luae066-B10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1089\/thy.2019.0085","article-title":"The long-term outcome of treatment for graves\u2019 hyperthyroidism","volume":"29","author":"Sjolin","year":"2019","journal-title":"Thyroid"},{"issue":"5","key":"2024062702115049100_luae066-B11","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/bjd.15423","article-title":"Recent advances in the understanding of severe cutaneous adverse reactions","volume":"177","author":"Adler","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/6\/luae066\/58340775\/luae066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/2\/6\/luae066\/58340775\/luae066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T02:12:06Z","timestamp":1719454326000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luae066\/7682504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,5,24]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luae066","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,24]]},"article-number":"luae066"}}